Cargando…
Viloxazine: Pediatric First Approval
Viloxazine (QELBREE(™)), a selective norepinephrine reuptake inhibitor, is being developed by Supernus Pharmaceuticals as a non-stimulant for the treatment of attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. This is a novel formulation of a pharmacological agent forme...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10575801/ https://www.ncbi.nlm.nih.gov/pubmed/34036533 http://dx.doi.org/10.1007/s40272-021-00453-3 |